Salmeterol/fluticasone dry powder inhaler approved for asthma

AirFluSal Forspiro (salmeterol/fluticasone) is now licensed for the treatment of severe asthma, in addition to COPD.

AirFluSal Forspiro is indicated in the regular treatment of adults aged 18 years and older with severe asthma in whom use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate.

The dry powder inhaler can be prescribed for patients not adequately controlled on a lower strength corticosteroid combination product or patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.

AirFluSal Forspiro contains 50 microgram salmeterol and 500 microgram fluticasone propionate per metered dose, the same as Seretide 500 Accuhaler. One inhalation is taken twice daily.

AirFluSal Forspiro is not intended to be used for the treatment of asthma when a fixed-dose combination of salmeterol and fluticasone is required for the first time. Patients should commence treatment with a fixed-dose combination containing a lower dose of the corticosteroid component and then be titrated up until control of asthma is achieved.

Once control is achieved and it is appropriate to titrate down to a lower strength of salmeterol/fluticasone not available for AirFluSal Forspiro, a change to an alternative fixed dose combination is required.

In COPD, AirFluSal Forspiro is indicated for use in adults with a history of repeated exacerbations and significant symptoms despite regular bronchodilator therapy who have a pre-bronchodilator FEV1 that is less than 60% of the predicted normal.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in